agency dedicated to leukemia, lymphoma, multiple myeloma, and Hodgkin's disease.
Other Complications About 10 per cent of patients with myeloma develop primary amyloidosis.
These facts may suggest that patients with multiple myeloma are more vulnerable to developing megaloblastic anemia than others.
AB - Many patients with multiple myeloma tend to have low serum cobalamin.
Where myeloma is suspected, urine and serum should be sent (see urine electrophoresis ).
There are a number of studies going on in the USA and UK using erythropoietin for people with multiple myeloma.
AB - The role of human herpesvirus 8 (HHV-8) in multiple myeloma (MM) remains controversial.
immunoglobulin produced by myeloma cells.
Multiple myeloma may rarely present or evolve into a plasma cell leukemia, typically in far advanced disease.
malignancyood malignancies, eg lymphoma or leukemia can sometimes be confused with multiple myeloma.
median survival for patients with myeloma is two years.
In myeloma, bortezomib affects the ability of myeloma cells to interact with the bone marrow microenvironment.
AB - A patient with multiple myeloma was treated with several cycles of chemotherapy and developed monoclonal IgA rheumatoid factor.
multiple myeloma was the suspected cause of the pleural lesions.
myeloma treated with local radiotherapy.
Introduction Bone pain is often the most difficult symptom to deal with for people who develop myeloma.
They are used to treat these problems in many types of cancers, including myeloma.
Choosing the right time to tell your child you have myeloma is not easy.
On 25 November 1998, Mr T was suffering intense pain and the consultant diagnosed myeloma.
This approach may help to keep the myeloma in remission for longer.
myeloma in remission for longer.
Thalidomide should be included in the therapeutic options for refractory myeloma.
multiple myeloma may be present for many years without symptoms.
Rather unexpectedly it was noted to have an effect in 30% of patients with advanced stage myeloma.
Aplidin(R) also demonstrated activity against a panel of 35 human multiple myeloma (MM) cell lines.
As all patients with symptomatic myeloma are now treated with long-term bisphosphonates, recurrent hypercalcaemia is not common unless there is disease progression.
myeloma plasma cells typically show a very low rate of proliferation and this complicates accurate analysis.
myeloma bone disease.
myeloma patients survive 10 years.
myeloma proteins were NEW for the heavy chain and REI for the light chain  .
This patient had been treated for five months for a stage I IgG lambda multiple myeloma.
AB - A 41-year-old male with IgG kappa multiple myeloma is described.
osteoclast activity in myeloma has not been clearly identified.
AB - Recently, several advances have been made in understanding the pathogenesis of multiple myeloma.
On a more basic level, we have an interest in the molecular pathogenesis of myeloma.
Controversy exists as to whether myeloma and AML originate from a single haematopoietic progenitor or arise from different cell lineages.
Management of myeloma should take account of the disease, its complications, and also psychosocial issues affecting the patient and their environment.
The median survival for patients with myeloma is two years.
Primary amyloidosis usually occurs as a complication of multiple myeloma.
It may also reappear in adults when the bone marrow is overactive, as in disorders such as pernicious anemia, multiple myeloma, and invasive (metastatic) cancer affecting bone marrow.
The word usage examples above have been gathered from various sources to reflect current and historial usage. They do not represent the opinions of YourDictionary.com.